Navigation Links
TGen and USC researchers find genetic markers to help fight diabetes
Date:6/16/2009

PHOENIX, Ariz. June 16, 2009 Translational Genomics Research Institute (TGen) scientists have identified five genetic biomarkers that could help lead to improved treatments, with fewer side-effects, for patients with diabetes.

TGen Senior Investigator Dr. Johanna DiStefano presented the findings in New Orleans on June 6, 2009, at the 69th Scientific Sessions of the American Diabetes Association.

"We identified genetic variants that may predict how well someone will respond to the common anti-diabetes drug, Actos,'' said Dr. DiStefano, Director of TGen's Diabetes, Cardiovascular & Metabolic Diseases Division. "The implications of these findings include determining which patients will best respond to the drug for the prevention or treatment of diabetes. In addition, this work lays the foundation for personalized medicine for patients with this disease.''

Personalized medicine involves the rapid application of laboratory discoveries to therapies, depending on the individual genetic make-up of each patient.

A TGen-led team, working with scientists from the University of Southern California's Keck School of Medicine, investigated why as many as 30-40 percent of diabetes patients treated with thiazolidinediones (TZDs), such as Actos, fail to respond to the drug with the expected improvement in insulin sensitivity.

TZDs are a class of insulin-sensitizing drugs used to treat type 2 diabetes mellitus (T2DM). TZDs are agonists for the nuclear receptor peroxisome proliferator-activated receptor-g (PPARG). Although the exact mechanism by which TZDs act is not yet known, data indicate that TZDs improve insulin sensitivity by direct and indirect effects on adipose tissue and muscle. TZD therapy can significantly lower diabetes incidence in at-risk subjects, suggesting this treatment may be an effective means to prevent the disease.

Previously, TGen and Keck investigators found that genetic variations in the PPARG gene w
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Vanderbilt researchers pioneer an advanced sepsis detection and management system
2. USC researchers identify DNA mutation that occurs at beginning point of T-cell lymphoma
3. Researchers identify 4 new targets for breast cancer
4. Researchers at Case Western Reserve discover a new way the body fights fungal infection
5. Off-label morning sickness drug deemed safe for fetuses -- Ben-Gurion U. researchers
6. Researchers identify four new targets for breast cancer
7. VBI researchers develop new method for breast cancer biomarker discovery
8. Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers
9. LSUHSC researchers first to document early signs for diabetes in kids as young as 7
10. Researchers work to boost effectiveness of the flu vaccine
11. Researchers develop the first climate-based model to predict Dengue fever outbreaks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... The World Scout League Commission (WSLC), an ... EMTs and firefighters, recently announced its decision to host ... raise charitable donations for age-related research. The five-kilometer race, ... held on March 29, 2015; registration will start at ... p.m. , To participate in the race, runners ...
(Date:2/27/2015)... Hispanics develop alcoholic liver disease (ALD), a common ... earlier than Whites/Caucasians or African Americans, according to a ... previous research indicated that Hispanics tend to have more ... published online in the journal Alcoholism: Clinical and Experimental ... pinpoint racial and ethnic disparities in the ages at ...
(Date:2/27/2015)... February 27, 2015 A new study ... correlation between men who cycle on a regular basis and ... the study suggests that the more hours per week a ... prostate cancer, leading to an increased importance on prostate cancer ... physicians to look more closely at patents’ risk factors for ...
(Date:2/27/2015)... Today, February 27th, is "Shine A Light On ... LXR Organics and Living Fuel, Inc. , ... awareness and promote prevention, rescue and restoration for people held ... IT Coalition, slavery is the 2nd largest global organized crime, ... countries around the world. Slavery includes bonded labor, forced labor, ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Altec ... LLP (BPW) has been chosen as their doc-link for ... GP, CRM and other complimentary solutions for their customers ... working with credit unions. Altec and BPW have worked ... doc-link’s integration to Dynamics GP. , “We are so ...
Breaking Medicine News(10 mins):Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... Metric Ton of CO2 ... in Emissions Possible, PITTSBURGH, May 28 As ... move the United States toward a,mandatory price for carbon ... provides the clearest picture yet of,the possible short-term effects ...
... PainSmart Infusion Pumps Undergo,Immediate Testing to ... MEETING, Pa., May 28 ECRI ... organization that,researches the best approaches to ... medical device alert on its Web ...
... Following are remarks by,Attorney General Michael B. Mukasey on ... Thank you, and good afternoon. I,m pleased to be ... the Justice Department is doing to,fight health care fraud. ... the Criminal Division, and everyone here for your hard,work., ...
... , , WEDNESDAY, May 28 (HealthDay News) -- Two new ... , Almost 15 percent of Americans are constipated at any ... of two reports in the May 29 issue of the ... on the efficacy of the experimental drug prucalopride on 620 ...
... provides targeted searches to Advanced Practice Clinicians, ... in the,delivery of clinical information to Advance Practice ... clinical,nurse specialists), has announced the launch of a ... )., As part of APCToday.com,s continued commitment ...
... ANGELES, May 28 Dr. Jeffrey Cummings, Medical,Director ... at UCLA,received the prestigious Ronald and Nancy Reagan ... team devote themselves to, discovering new,treatments and methods ... disorders., In his speech of acceptance at ...
Cached Medicine News:Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 2Health News:Establishing a Price for Carbon Emissions in the U.S. Would Spur Immediate Reductions in Energy Consumption and More Efficient Use of Power Generators, Study by Carnegie Mellon Researchers Shows 3Health News:ECRI Institute Issues Priority Alert About Two Infusion Pumps 2Health News:Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Department's Efforts to Combat Healthcare Fraud Nationwide 2Health News:Prepared Remarks of Attorney General Michael B. Mukasey on the Justice Department's Efforts to Combat Healthcare Fraud Nationwide 3Health News:Two Drugs Show Promise Against Severe Constipation 2Health News:Two Drugs Show Promise Against Severe Constipation 3Health News:APCTODAY.com and Convera(R) Launch Vertical Search Site for Advanced Practice Clinicians 2
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... study published in the Proceedings of the ... that showed when ibrutinib (IMBRUVICA ® ) was ... suppression of tumor growth was enhanced suggesting a ... hematologic cancers and solid tumors with the combination. ...
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... forma net operating loss (NOL) guidance and its cash ...  Isis, significantly improved financial results were due in large ... the Company received from its partners.  Isis, pro forma ... 60% improvement over its 2013 NOL of $40.2 million. ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... 2, 2011 Men who take non-steroidal anti-inflammatory drugs three ... times more likely to have erectile dysfunction compared to men ... Kaiser Permanente study published online in The Journal of ... trend toward this same finding, this observational study used electronic ...
... SILVER SPRING, Md., March 2, 2011 The U.S. ... that manufacture, distribute, or market certain unapproved prescription oral ... be legally marketed in the United States. ... cough, cold, and allergy drug products have not been ...
Cached Medicine Technology:Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 2Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 3FDA Prompts Removal of Unapproved Drugs From Market 2FDA Prompts Removal of Unapproved Drugs From Market 3
EC+ Extra Care Bariatric Bed...
... feature folding head end and foot end deck panels ... end and foot end deck panels folded the overall ... This compact length makes storage, delivery and pick up ... not available on Model 4748B, Basic Maxi Rest bariatric ...
... I system is a unique ... combines dual width capability with ... roll" design. Specifically developed to ... patients, the easy-to-use Tri-Flex I ...
... system is a unique healthcare ... dual width capability with a ... design. Specifically developed to accommodate ... the easy-to-use Tri-Flex I system ...
Medicine Products: